|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
|
|||
|
FORM 8-K
|
|||
|
CURRENT REPORT
|
|||
|
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
|||
| Date of Report (Date of earliest event reported) April 3, 2014 |
|
RETROPHIN, INC.
|
|||
|
(Exact name of registrant as specified in its charter)
|
|
Delaware
|
001-36257
|
27-4842691
|
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification No.)
|
|
|
777 Third Avenue, 22nd Floor, New York, NY
|
10017
|
||
|
(Address of principal executive offices)
|
(Zip Code)
|
||
|
Registrant’s telephone number, including area code (646) 837-5863
|
|
(Former name or former address, if changed since last report.)
|
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|||
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))
|
||
Item 8.01 Other Events.
On April 3, 2014, Retrophin, Inc. (the “Registrant”) provided notice to the wholesaler of its Chenodal® product that effective immediately, the Registrant had increased the price of a package of 100 250mg tablets of Chenodal from $9,460 to $47,300.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
RETROPHIN, INC.
|
|||
|
Date: April 3, 2014
|
By:
|
/s/ Marc Panoff | |
|
Name: Marc Panoff
|
|||
|
Title: Chief Financial Officer
|
|||